Edition:
United States

Pain Therapeutics Inc (PTIE.OQ)

PTIE.OQ on NASDAQ Stock Exchange Global Select Market

3.90USD
22 Nov 2017
Change (% chg)

$0.05 (+1.30%)
Prev Close
$3.85
Open
$3.90
Day's High
$3.95
Day's Low
$3.85
Volume
5,917
Avg. Vol
63,251
52-wk High
$9.31
52-wk Low
$3.10

Chart for

About

Pain Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on drug development efforts on disorders of the nervous system, such as chronic pain. The Company's lead drug candidate, REMOXY, is an abuse-deterrent, oral formulation of oxycodone (CII). The Company's other products is FENROCK. REMOXY is a... (more)

Overall

Beta: 2.08
Market Cap(Mil.): $25.72
Shares Outstanding(Mil.): 6.60
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 189.94 15.47
EPS (TTM): -- -- --
ROI: -- -10.73 11.81
ROE: -- -36.69 15.76

BRIEF-Pain therapeutics reports Q3 loss per share $0.40

* Pain therapeutics reports third quarter 2017 financial results

Nov 01 2017

BRIEF-Pain Therapeutics announces upcoming meeting with FDA

* Pain Therapeutics - ‍U.S. FDA agreed to pre-nda guidance meeting to discuss co's NDA resubmission for remoxy er as a treatment for severe chronic pain​

Oct 30 2017

BRIEF-Pain Therapeutics announces successful Phase I clinical study for PTI-125

* Pain Therapeutics announces successful Phase I clinical study for PTI-125

Oct 24 2017

BRIEF-National Institute on Drug Abuse awards Pain Therapeutics $2.2 mln grant

* National Institute on Drug Abuse awards Pain Therapeutics $2.2 million grant Source text for Eikon: Further company coverage:

Sep 18 2017

BRIEF-Pain Therapeutics reports Q2 loss per share $0.64

* Pain Therapeutics reports Q2 2017 financial results and mid-year corporate update

Aug 09 2017

BRIEF-Pain Therapeutics announces FDA clears investigational new drug application for PTI-125

* Pain Therapeutics announces FDA has cleared an investigational new drug (IND) application for PTI-125

Jul 31 2017

Competitors

Earnings vs. Estimates